Cancer immunotherapy utilizes monoclonal antibodies directed against immune checkpoint proteins such as PD-1, PD-L1, and CTLA-4 to enable T-cell recognition of tumor cells, and delivers the antitumor immune response. This evidence concerns the gene CD274 and neoplasm.